OMS103HP + Vehicle
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Anterior Cruciate Ligament Reconstruction
Conditions
Anterior Cruciate Ligament Reconstruction
Trial Timeline
Oct 1, 2004 → Mar 1, 2011
NCT ID
NCT00245271About OMS103HP + Vehicle
OMS103HP + Vehicle is a phase 3 stage product being developed by Omeros Corporation for Anterior Cruciate Ligament Reconstruction. The current trial status is completed. This product is registered under clinical trial identifier NCT00245271. Target conditions include Anterior Cruciate Ligament Reconstruction.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00624845 | Phase 2/3 | Completed |
| NCT00226772 | Phase 3 | Completed |
| NCT00226759 | Phase 3 | Completed |
| NCT00245271 | Phase 3 | Completed |
Competing Products
9 competing products in Anterior Cruciate Ligament Reconstruction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| PDE5 Inhibitors | Eli Lilly | Pre-clinical | 23 |
| Rosuvastatin | AstraZeneca | Approved | 85 |
| Diagnostic procedures | Bayer | Approved | 82 |
| MSB-CAR001 Combined With Hyaluronan + Hyaluronan | Mesoblast | Phase 1/2 | 36 |
| Topical Prednisolone Acetate 1% | Ocular Therapeutix | Approved | 80 |
| Valganciclovir Hydrochloride + Ganciclovir Sodium + Placebo Oral Tablet + Topical placebo | Pacific Biosciences | Phase 2/3 | 57 |
| Abciximab local infusion | Atrium Therapeutics | Pre-clinical | 15 |
| ADX-102 Ophthalmic Solution (0.5%) + Vehicle of ADX-102 Ophthalmic Solution | Aldeyra Therapeutics | Phase 3 | 69 |
| NS2 + Prednisolone acetate ophthalmic suspension (1%) | Aldeyra Therapeutics | Phase 2 | 44 |